LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Becton Dickinson and Co

Geschlossen

BrancheGesundheitswesen

175.31 1.95

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

170.98

Max

175.54

Schlüsselkennzahlen

By Trading Economics

Einkommen

27M

330M

Verkäufe

104M

5.3B

KGV

Branchendurchschnitt

33.915

56.602

EPS

3.35

Dividendenrendite

2.49

Gewinnspanne

6.259

Angestellte

70,000

EBITDA

93M

546M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+19.81% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

2.49%

2.45%

Nächstes Ergebnis

7. Aug. 2025

Nächste Dividendenausschüttung

30. Juni 2025

Nächstes Ex-Dividendendatum

9. Juni 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-15B

50B

Vorheriger Eröffnungskurs

173.36

Vorheriger Schlusskurs

175.31

Nachrichtenstimmung

By Acuity

29%

71%

73 / 382 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Becton Dickinson and Co Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

1. Mai 2025, 11:18 UTC

Ergebnisse

Becton 2Q Net Down, Warns of Tariff Hit on 2025 EPS

5. Feb. 2025, 22:09 UTC

Akquisitionen, Fusionen, Übernahmen

Becton Dickinson to Separate From Bioscience and Diagnostic Solutions Business

7. Nov. 2024, 12:59 UTC

Ergebnisse

Becton Dickinson Profit Rises as Acquisition Buoys Sales - Update

7. Nov. 2024, 12:56 UTC

Ergebnisse

Becton Dickinson Fiscal 4Q Profit Rises as Acquisition Buoys Sales

1. Mai 2025, 10:33 UTC

Ergebnisse

Becton Dickinson Cuts FY25 Adj EPS View on Tariff Impact

1. Mai 2025, 10:33 UTC

Ergebnisse

Becton Dickinson FY25 Adj EPS View Includes an Estimated Tariff Impact of Approximately 25c

1. Mai 2025, 10:32 UTC

Ergebnisse

Becton Dickinson Sees FY25 Organic Rev Growth Guidance of 3.0% to 3.5% >BDX

1. Mai 2025, 10:32 UTC

Ergebnisse

Becton Dickinson Narrows FY25 View To Rev $21.8B-$21.9B >BDX

1. Mai 2025, 10:31 UTC

Ergebnisse

Becton Dickinson Intends To Invest $2.5 B in U.S. Manufacturing Capacity Over the Next 5 Years >BDX

1. Mai 2025, 10:31 UTC

Ergebnisse

Becton Dickinson: Taking 'Decisive Mitigation Actions to Navigate the Current Macro Environment' >BDX

1. Mai 2025, 10:30 UTC

Ergebnisse

Becton Dickinson Updates full-Yr Fiscal 2025 Guidance and Provides Estimated Tariff Impact >BDX

1. Mai 2025, 10:30 UTC

Ergebnisse

Becton Dickinson Sees FY Adj EPS $14.06-Adj EPS $14.34 >BDX

1. Mai 2025, 10:30 UTC

Ergebnisse

Becton Dickinson 2Q Net $308M >BDX

1. Mai 2025, 10:30 UTC

Ergebnisse

Becton Dickinson 2Q EPS $1.07 >BDX

1. Mai 2025, 10:30 UTC

Ergebnisse

Becton Dickinson 2Q Adj EPS $3.35 >BDX

1. Mai 2025, 10:30 UTC

Ergebnisse

Becton Dickinson 2Q Rev $5.3B >BDX

5. Feb. 2025, 21:56 UTC

Ergebnisse

Correct: Becton Dickinson Sees 2025 Adj EPS $14.30-Adj EPS $14.60 >BDX

5. Feb. 2025, 21:54 UTC

Ergebnisse

Becton Dickinson Sees 2025 EPS $14.30-EPS $14.60 >BDX

5. Feb. 2025, 21:54 UTC

Ergebnisse

Becton Dickinson Sees 2025 GAAP Rev Growth 7.9% to 8.4% >BDX

5. Feb. 2025, 21:53 UTC

Ergebnisse

Becton Dickinson Sees 2025 Rev $21.7B-$21.9B >BDX

5. Feb. 2025, 21:30 UTC

Ergebnisse

Becton Dickinson 1Q Adj EPS $3.43 >BDX

5. Feb. 2025, 21:30 UTC

Ergebnisse

Becton Dickinson 1Q Rev $5.2B >BDX

5. Feb. 2025, 21:30 UTC

Ergebnisse

Becton Dickinson 1Q Net $303M >BDX

5. Feb. 2025, 21:30 UTC

Ergebnisse

Becton Dickinson 1Q EPS $1.04 >BDX

7. Nov. 2024, 11:36 UTC

Ergebnisse

Becton Dickinson Sees FY25 Rev $21.9B-$22.1B >BDX

7. Nov. 2024, 11:35 UTC

Ergebnisse

Becton Dickinson Sees FY25 Adj EPS $14.25-Adj EPS $14.60 >BDX

7. Nov. 2024, 11:30 UTC

Ergebnisse

Becton Dickinson 4Q EPS $1.45 >BDX

7. Nov. 2024, 11:30 UTC

Ergebnisse

Becton Dickinson 4Q Adj EPS $3.81 >BDX

7. Nov. 2024, 11:30 UTC

Ergebnisse

Becton Dickinson 4Q Rev $5.4B >BDX

7. Nov. 2024, 11:30 UTC

Ergebnisse

Becton Dickinson 4Q Cont Ops EPS $1.45 >BDX

Peer-Vergleich

Kursveränderung

Becton Dickinson and Co Prognose

Kursziel

By TipRanks

19.81% Vorteil

12-Monats-Prognose

Durchschnitt 206.4 USD  19.81%

Hoch 261 USD

Tief 172 USD

Basierend auf 12 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Becton Dickinson and Co – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

12 ratings

4

Buy

8

Halten

0

Sell

Technischer Score

By Trading Central

167 / 206.99Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Weak Bearish Evidence

Langfristig

Weak Bearish Evidence

Stimmung

By Acuity

73 / 382 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Becton Dickinson and Co

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.